Comparison of 131I-labelled anti-episialin 139H2 with cisplatin, cyclophosphamide or external-beam radiation for anti-tumor efficacy in human ovarian cancer xenografts
✍ Scribed by Carla F. M. Molthoff; Herbert M. Pinedo; Hennie M. M. Schlüper; Derk H. Rutgers; Epie Boven
- Publisher
- John Wiley and Sons
- Year
- 1992
- Tongue
- French
- Weight
- 772 KB
- Volume
- 51
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
✦ Synopsis
Three human ovarian cancer xenografts of different origin and grown S. C. in nude mice as well-established tumors were studied for their sensitivity to cisplatin (CDDP), cyclophosphamide (CTX), '3'I-labelled anti-episialin monoclonal antibody (MAb) I39H2, or external-beam radiotherapy. The maximum tolerated dose of CDDP given weekly i.v. X 2 induced a tumor growth inhibition (GI) of 77.5% and 85.1% of the serous xenografts Ov.Ri(C) and OVCAR-3, respectively. The mucinous xenograft Ov.Pe was relatively resistant to CDDP. The maximum tolerated dose of CTX, given i.p. X 2 with a 2-week interval, induced a GI between 52.9% and 59.7% for each of the 3 xenografts. Radioimmunotherapy with 500-750 pCi l3Il- specific MAb 139H2, administered i.v. X 2 with a 2-week interval, was more effective than CDDP or CTX. The 500 pCi I3'1-MAb 139H2 schedule induced 100% GI in Ov.Ri(C) xenografts and all tumors were cured. The same schedule was slightly less effective in OVCAR-3 xenografts, but complete tumor regressions could still be obtained. Ov.Pe xenografts were least sensitive to radioimmunotherapy. The 2 injections of 500 pCi '3tl-control MAb gave only transient growth inhibition of OVCAR-3 and Ov.Pe tumors, but gave complete regressions of Ov.Ri(C) xenografts. Biodistribution using tracer doses of I3'I-MAb I39H2 and t251-control MAb showed different degrees of specificity for MAb 1391-12 in the 3 xenografts. Radiation doses absorbed in Ov.Ri(C), OVCAR-3 and Ov.Pe xenografts per I0 pCi injected dose were 30,4 I and 29 cGy respectively. Treatment with 10 Gy external-beam radiation suggested that the effects of radioimmunotherapy in each tumor line were related to the intrinsic radiosensitivity of the xenografts.